WuXi Biologics 2023 Net Profit Fell on Higher Expenses, Impairment Losses
By Tracy Qu
WuXi Biologics (Cayman) said its net profit in 2023 declined mainly due to higher expenses and impairment losses.
The biotech company's net profit fell 23.1% to 3.40 billion yuan ($471 million) compared with a profit of CNY4.42 billion in 2022.
However, revenue rose 11.6% to CNY17.03 billion, it said late Tuesday.
An increase in finance costs, research and development as well as higher impairments on trade and other receivables weighed on the company's bottomline.
Shares of the WuXi family of biotech and research companies have been under pressure since the start of the year on worries about potential U.S. sanctions.
WuXi Biologics reiterated that it remains committed to operating in accordance with applicable laws and regulations in all jurisdictions where it has business operations.
Write to Tracy Qu at tracy.qu@wsj.com
(END) Dow Jones Newswires
March 26, 2024 21:26 ET (01:26 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise